{"name": "Biogen Idec",
 "permalink": "biogen-idec",
 "crunchbase_url": "http://www.crunchbase.com/company/biogen-idec",
 "homepage_url": "http://www.biogenidec.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "781-464-2000",
 "description": "",
 "created_at": "Wed Dec 22 07:12:21 UTC 2010",
 "updated_at": "Wed Feb 15 02:49:36 UTC 2012",
 "overview": "\u003Cp\u003EBiogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, Biogen Idec is the world\u0026#8217;s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[141,
       58],
      "assets/images/resized/0011/5048/115048v1-max-150x150.png"],
     [[141,
       58],
      "assets/images/resized/0011/5048/115048v1-max-250x250.png"],
     [[141,
       58],
      "assets/images/resized/0011/5048/115048v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "George",
      "last_name": "A. Scangos",
      "permalink": "george-a-scangos",
      "image": null}},
   {"is_past": true,
    "title": "CEO",
    "person":
     {"first_name": "Mr.",
      "last_name": "James C. Mullen",
      "permalink": "mr-james-c-mullen",
      "image": null}},
   {"is_past": true,
    "title": "Executive Chairman",
    "person":
     {"first_name": "William",
      "last_name": "Rastetter",
      "permalink": "william-rastetter",
      "image": null}},
   {"is_past": true,
    "title": "President/ COO / VP, International / VP, Operations / Director, Facilities \u0026 Engineering",
    "person":
     {"first_name": "Mr.",
      "last_name": "James C. Mullen",
      "permalink": "mr-james-c-mullen",
      "image": null}},
   {"is_past": true,
    "title": "VP, Research",
    "person":
     {"first_name": "Vicki",
      "last_name": "L. Sato",
      "permalink": "vicki-l-sato",
      "image":
       {"available_sizes":
         [[[126,
            150],
           "assets/images/resized/0026/7595/267595v1-max-150x150.jpg"],
          [[130,
            154],
           "assets/images/resized/0026/7595/267595v1-max-250x250.jpg"],
          [[130,
            154],
           "assets/images/resized/0026/7595/267595v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "VP Oncology",
    "person":
     {"first_name": "Alessandra",
      "last_name": "Cesano",
      "permalink": "alessandra-cesano",
      "image":
       {"available_sizes":
         [[[112,
            150],
           "assets/images/resized/0026/6361/266361v1-max-150x150.jpg"],
          [[120,
            160],
           "assets/images/resized/0026/6361/266361v1-max-250x250.jpg"],
          [[120,
            160],
           "assets/images/resized/0026/6361/266361v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Senior Director, Oncology",
    "person":
     {"first_name": "Pratik",
      "last_name": "Multani",
      "permalink": "pratik-multani",
      "image":
       {"available_sizes":
         [[[122,
            150],
           "assets/images/resized/0026/4789/264789v1-max-150x150.png"],
          [[157,
            192],
           "assets/images/resized/0026/4789/264789v1-max-250x250.png"],
          [[157,
            192],
           "assets/images/resized/0026/4789/264789v1-max-450x450.png"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Board Chairman",
    "person":
     {"first_name": "Mr.",
      "last_name": "James C. Mullen",
      "permalink": "mr-james-c-mullen",
      "image": null}},
   {"is_past": true,
    "title": "Leading Position",
    "person":
     {"first_name": "Robert",
      "last_name": "Becker",
      "permalink": "robert-becker",
      "image":
       {"available_sizes":
         [[[80,
            95],
           "assets/images/resized/0026/6859/266859v1-max-150x150.jpg"],
          [[80,
            95],
           "assets/images/resized/0026/6859/266859v1-max-250x250.jpg"],
          [[80,
            95],
           "assets/images/resized/0026/6859/266859v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "133 Boston Post Road",
    "address2": "",
    "zip_code": "02493",
    "city": "Weston",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Biogen buys Neurimmune unit for up to $427M",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 21,
    "source_url": "http://www.masshightech.com/stories/2010/12/20/daily14-Biogen-buys-Neurimmune-unit-for-up-to-427M.html",
    "source_text": "",
    "source_description": "Biogen buys Neurimmune unit for up to $427M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Biogen Idec",
      "permalink": "biogen-idec"}},
   {"description": "saw its stock rise more than 5 percent Monday morning, following the release of positive late-stage data for its experimental oral treatment for multiple sclerosis.",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 11,
    "source_url": "http://www.masshightech.com/stories/2011/04/11/daily8-Biogen-sees-boost-from-new-oral-MS-drug-candidate.html",
    "source_text": null,
    "source_description": "Biogen sees boost from new oral MS drug candidate",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Biogen Idec",
      "permalink": "biogen-idec"}},
   {"description": "the European Medicines Agency\u00e2\u20ac\u2122s Pediatric Committee has agreed to the pediatric investigational plan for the companies\u00e2\u20ac\u2122 Factor IX Fc fusion protein (rFIXFc) for patients with hemophilia B",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 9,
    "source_url": "http://www.masshightech.com/stories/2011/05/09/daily8-Biogen-gets-European-OK-for-pediatric-trial-of-hemophilia-therapy.html",
    "source_text": null,
    "source_description": "Biogen gets European OK for pediatric trial of hemophilia therapy",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Biogen Idec",
      "permalink": "biogen-idec"}},
   {"description": "researchers have identified a potential new approach to treating multiple sclerosis",
    "stoned_year": 2011,
    "stoned_month": 7,
    "stoned_day": 5,
    "source_url": "http://www.masshightech.com/stories/2011/07/04/daily9-Biogen-reports-finding-new-approach-to-MS-treatments.html",
    "source_text": null,
    "source_description": "Biogen reports finding new approach to MS treatments",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Biogen Idec",
      "permalink": "biogen-idec"}},
   {"description": "Biogen Idec to buy Stromedix for up to $562M ",
    "stoned_year": 2012,
    "stoned_month": 2,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2012/02/13/daily13-Biogen-Idec-to-buy-Stromedix-for-up-to-562M-.html",
    "source_text": "",
    "source_description": "Biogen Idec to buy Stromedix for up to $562M ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Biogen Idec",
      "permalink": "biogen-idec"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:BIIB"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        95],
       "assets/images/resized/0017/4298/174298v1-max-150x150.png"],
      [[250,
        158],
       "assets/images/resized/0017/4298/174298v1-max-250x250.png"],
      [[450,
        285],
       "assets/images/resized/0017/4298/174298v1-max-450x450.png"]],
    "attribution": null}],
 "external_links":
  []}